Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
CC transcript
Inv. presentation
Quarterly results
|
|
Ensysce Biosciences, Inc. (LACQ)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
8-K
| Quarterly results |
| 06/02/2023 |
8-K
| Other Events Interactive Data |
| 05/15/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: _______ Initial Exercise Date: May [_], 2023 THIS SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on [____,___] 12 but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defin...",
"PREFUNDED COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: ______ Initial Exercise Date: May [_],2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the m...",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: 126,061 Initial Exercise Date: May 12, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, H.C. Wainwright & Co., LLC or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on May 10, 2028 but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation , up to 126,061 shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is being issued pursuant to that certain Engagement A...",
"NOTICE OF EXERCISE TO: Ensysce Biosciences, Inc., The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant , and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. Payment shall take the form of : [ ] in lawful money of the United States; or [ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2, to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2. Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: __________________...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of May 10, 2023, between Ensysce Biosciences, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser a...",
"Ensysce Biosciences Investor Relations Contact:" |
|
| 03/24/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 02/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"DGCL",
"COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: _______ Initial Exercise Date: February 6, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on August 7, 2028 but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings ...",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: _______ Initial Exercise Date: February 6, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on February 2, 2028 but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is issued pursuant to that certain Engagement Agreement, by...",
"Letter re: Registration Statement on Form S-3",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of February 2, 2023, between Ensysce Biosciences, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION ...",
"Ensysce Biosciences Investor Relations Contact:",
"Investor Contact" |
|
| 02/01/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...|
Docs:
|
"Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of its Common Stock SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. , a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’ s common stock held of record as of 5:00 p.m. Eastern Time on February 13, 2023. The outstanding shares of Series A Preferred Stock will vote together with the outstanding shares of the Company’ s common stock, as a single class, exclusively with respect to a reverse stock split..." |
|
| 01/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/08/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 11/14/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/27/2022 |
8-K
| Quarterly results |
| 09/20/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/16/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/08/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &... |
| 08/11/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Original Issue Date: August 8, 2022 Original Principal Amount: $ Purchase Price: $ Fixed Conversion Price : $0.5450 SENIOR SECURED CONVERTIBLE NOTE DUE February 7, 2024",
"NOTICE OF EXERCISE TO: Ensysce Biosciences, Inc., The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant , and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. Payment shall take the form of : ☐ in lawful money of the United States; or ☐ if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2, to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2. Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: The Warran...",
"Exhibit10.6",
"Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing SAN DIEGO, August 9, 2022 — Ensysce Biosciences, Inc. , a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today that it has completed its previously announced private placement under a securities purchase agreement with institutional investors for senior secured convertible notes and warrants exercisable for Ensysce common stock for an aggregate investment of $8 million. The final funding by the Investors of $4 million, prior to fees and offering expenses, was dated as of August 8, 2022, with funds received in full on August 9, 2022. As previously reported the Notes are convertible into shares of Ensysce common stock ..." |
|
| 08/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"SENIOR SECURED CONVERTIBLE NOTE DUE DECEMBER 29, 2023 THIS SENIOR SECURED CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Senior Secured Convertible Notes of Ensysce Biosciences, Inc., a Delaware corporation , having its principal place of business at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California, 92037 , designated as its Senior Secured Convertible Note due December 29, 2023 . FOR VALUE RECEIVED, the Company promises to pay to __________ or its registered assigns , or shall have paid pursuant to the terms hereunder, the principal sum of $___________ on December 29, 2023 or such earlier date as this Note is required or permitted to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate unconverted and then outstanding principal ...",
"NOTICE OF EXERCISE TO: Ensysce Biosciences, Inc., The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant , and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. Payment shall take the form of : ☐ in lawful money of the United States; or ☐ if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2, to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2. Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: __________..." |
|
| 07/06/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/17/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 03/31/2022 |
8-K
| Quarterly results |
| 02/08/2022 |
8-K
| Quarterly results |
| 01/27/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &... |
| 12/27/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/16/2021 |
8-K
| Quarterly results|
Docs:
|
"Ensysce Biosciences, Inc. Unaudited Condensed Consolidated Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Federal grants $ 1,200,816 $ 827,639 $ 1,895,907 $ 3,514,720 Operating expenses: Research and development 1,714,635 892,991 2,502,232 3,136,207 General and administrative 16,372,976 339,422 17,257,361 898,470 Total operating expenses 18,087,611 1,232,413 19,759,593 4,034,677 Loss from operations Total other income , net 1,955,280 340,742 Net income $ $ 1,550,506 $ $ Ensysce Biosciences, Inc. Unaudited Condensed Consolidated Balance Sheets" |
|
| 11/10/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/27/2021 |
8-K
| Quarterly results |
| 08/16/2021 |
8-K
| Quarterly results|
Docs:
|
"Ensysce Biosciences, Inc. Unaudited Condensed Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Federal grants $ 444,516 $ 1,824,681 $ 695,091 $ 2,687,081 Operating expenses: Research and development 463,219 1,404,246 787,595 2,243,217 General and administrative 393,914 281,354 884,386 559,047 Total operating expenses 857,133 1,685,600 1,671,981 2,802,264 Income from operations 139,081 Total other income , net Net loss $ $ $ $ Ensysce Biosciences, Inc. Unaudited Condensed Consolidated Balance Sheets" |
|
| 07/21/2021 |
8-K
| Investor presentation |
| 07/08/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/07/2021 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modifications to Rig...|
Docs:
|
"THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LEISURE ACQUISITION CORP. Leisure Acquisition Corp. , a corporation existing under the General Corporation Law of the State of Delaware , hereby certifies as follows: 1. The name of the Corporation is “Leisure Acquisition Corp.” The Corporation was incorporated by the filing of its original Certificate of Incorporation, under the name GLL Acquisition Corp., with the Secretary of State of the State of Delaware on September 11, 2017 and was amended by the Certificate of Amendment, which was filed with the Secretary of State of Delaware on September 11, 2017 . 2. A first amended and restated certificate of incorporation was filed with the Secretary of State of the State of Delaware on November 30, 2017 . A second amended and restated ...",
"ENSYSCE BIOSCIENCES, INC. AMENDED AND RESTATED BYLAWS SECTION 1 -STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders of Ensysce Biosciences, Inc., a Delaware corporation , for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting shall be held at the place, if any, within or without the State of Delaware, on the date and at the time that the Board of Directors of the Corporation shall each year fix. Unless stated otherwise in the notice of the annual meeting of the stockholders of the Corporation, such annual meeting shall be at the principal office of the Corporation. Section 1.2. Advance Notice of Nominations and Proposals of Business. Nominations of persons for elec...",
"RECITALS",
"Legal Entity Jurisdiction of Organization" |
|
|
|
|